BioLineRx‘s Immunotherapy AGI-134 Receives FDA’s Biological Product Designation
News
The U.S. Food and Drug Administration has granted BioLineRx’s investigational immunotherapy AGI-134 a biological product designation, making the company eligible for 12-year market exclusivity after the treatment is approved in the ... Read more